• Ines Mader
  • Patrizia E. Fürst-Weger
  • Robert M. Mader
  • Elisabeth I. Semenitz
  • Robert Terkola
  • Sabine M. Wassertheurer


Dependent on the extravasated agent, a series of general emergency measures should be considered. Particularly in the case of vesicant substances, these measures are to be completed by substance specific interventions, unfortunately not available for all agents.


Clin Oncol Cytotoxic Agent None None Fibrin Sealant Vinca Alkaloid 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. [1]
    Laughlin RA, Landeen JM, Habal MB: The management of inadvertent subcutaneous adriamycin infiltration. Am J Surg 137: 408–412, 1979.PubMedCrossRefGoogle Scholar
  2. [2]
    Barlock AL, Howser DM, Hubbard SM: Nursing management of adriamycin extravasation. Am J Nurs 79: 94–96, 1979.PubMedGoogle Scholar
  3. [3]
    Cox K, Stuart-Harris R, Abdini G, et al: The management of cytotoxicdrug extravasation: guide-lines drawn up by a working party for the Clinical Oncological Society of Australia. Med J Aust 148: 185–189, 1988.PubMedGoogle Scholar
  4. [4]
    Brown AS, Hoelzer DJ, Piercy SA: Skin necrosis from extravasation of intravenous fluids in children. Plast Reconstr Surg 64: 145–150, 1979.PubMedCrossRefGoogle Scholar
  5. [5]
    Heckler FR: Current thoughts on extravasation injuries. Clin Plast Surg 16: 557–563, 1989.PubMedGoogle Scholar
  6. [6]
    Wang JJ, Cortes E, Sinks LF, et al: Therapeutic effect and toxicity of adriamycin in patients with neoplastic disease. Cancer 28: 837–843, 1971.PubMedCrossRefGoogle Scholar
  7. [7]
    Rudolph R, Stein RS, Pattillo RA: Skin ulcers due to adriamycin. Cancer 38: 1087–1094, 1976.PubMedCrossRefGoogle Scholar
  8. [8]
    Bowers DG, Lynch JB: Adriamycin extravasation. Plast Reconstr Surg 61: 86–92, 1978.PubMedCrossRefGoogle Scholar
  9. [9]
    Daniel RK, Williams HB: The free transfer of skin flaps by microvascular anastomoses. An experimental study and a reappraisal. Plast Reconstr Surg 52: 16–31, 1973.PubMedCrossRefGoogle Scholar
  10. [10]
    Yosowitz P, Ekland DA, Shaw RC, et al: Peripheral intravenous infiltration necrosis. Ann Surg 182: 553–556, 1975.PubMedCrossRefGoogle Scholar
  11. [11]
    Lynch DJ, Key JC, White RR: Management and prevention of infiltration and extravasation injury. Surg Clin North Am 59: 939–949, 1979.PubMedGoogle Scholar
  12. [12]
    Upton J, Mulliken JB, Murray JE: Major intravenous extravasation injuries. Am J Surg 137: 497–506, 1979.PubMedCrossRefGoogle Scholar
  13. [13]
    Sonneveld P, Wassenaar HA, Nooter K: Long persistence of doxorubicin in human skin after extravasation. Cancer Treat Rep 68: 895–896, 1984.PubMedGoogle Scholar
  14. [14]
    Dorr RT, Dordal MS, Koenig LM, et al: High levels of doxorubicin in the tissues of a patient experiencing extravasation during a 4-day infusion. Cancer 64: 2462–2464, 1989.PubMedCrossRefGoogle Scholar
  15. [15]
    Ignoffo RJ, Friedman MA: Therapy of local toxicities caused by extravasation of cancer chemotherapeutic drugs. Cancer Treat Rev 7: 17–27, 1980.PubMedCrossRefGoogle Scholar
  16. [16]
    Linder RM, Upton J, Osteen R: Management of extensive doxorubicin hydrochloride extravasation injuries. J Hand Surg 8: 32–38, 1983.Google Scholar
  17. [17]
    Montrose PA: Extravasation management. Semin Oncol Nurs 3: 128–132, 1987.PubMedCrossRefGoogle Scholar
  18. [18]
    Wetmore N: Extravasation. The dreaded complication. NITA 8: 47–49, 1985.PubMedGoogle Scholar
  19. [19]
    Köstering H, Nagel GA: Prophylaxe und Therapie von Zytostatika-Hautnekrosen. Onkologie 6: 317–320, 1980.Google Scholar
  20. [20]
    Faehnrich J: Extravasation. NITA 7: 49–52, 1984.Google Scholar
  21. [21]
    Larson DL: Treatment of tissue extravasation by antitumor agents. Cancer 49: 1796–1799, 1982.PubMedCrossRefGoogle Scholar
  22. [22]
    Beason R: Antineoplastic vesicant extravasation. J Intraven Nurs 13: 11 1114, 1990.Google Scholar
  23. [23]
    Cohen SC, DiBella NJ, Michalak JC: Recall injury from adriamycin. Ann Intern Med 83: 232, 1975.PubMedCrossRefGoogle Scholar
  24. [24]
    Meehan JL, Sporn JR: Case report of taxol administration via central vein producing a recall reaction at a site of prior taxol extravasation. J Natl Cancer Inst 86: 1250–1251, 1994.PubMedCrossRefGoogle Scholar
  25. [25]
    Shapiro J, Richardson GE: Paclitaxel-induced “recall” soft tissue injury occuring at the site of previous extravasation with subsequent intravenous treatment in a different limb. J Clin Oncol 12: 2237–2238, 1994.PubMedGoogle Scholar
  26. [26]
    Haskell CM, Silverstein MJ, Rangel DM, et al: Multimodality cancer therapy in man — a pilot study of adriamycin by arterial infusion. Cancer 33: 1485–1490, 1974.CrossRefGoogle Scholar
  27. [27]
    Donaldson SS, Glick JM, Wilbur JR: Adriamycin activating a recall phenomenon after radiation therapy. Ann Intern Med 81: 407–408, 1974.PubMedCrossRefGoogle Scholar
  28. [28]
    San Angel F: Current controversies in chemotherapy administration. J Intraven Nurs 18: 16–23, 1995.Google Scholar
  29. [29]
    Mullin S, Beckwith MC, Tyler LS: Prevention and management of antineoplastic extravasation injury. Hosp Pharm 35: 57–76, 2000.Google Scholar
  30. [30]
    Reilly JJ, Neifeld JP, Rosenberg SA: Clinical course and management of accidental adriamycin extravasation. Cancer 40: 2053–2056, 1977.PubMedCrossRefGoogle Scholar
  31. [31]
    MacCara ME: Extravasation: a hazard of intravenous therapy. Drug Intell Clin Pharm 17: 713–717, 1983.PubMedGoogle Scholar
  32. [32]
    Preuss P, Partoft S: Cytostatic extravasations. Ann Plast Surg 19: 323–327, 1987.PubMedCrossRefGoogle Scholar
  33. [33]
    Ayalon A, Anner H, Berlatzky Y, et al: A life-threatening complication of the infusion pump. Lancet 1: 853–854, 1978.PubMedCrossRefGoogle Scholar
  34. [34]
    Spiegel RJ: The acute toxicities of chemotherapy. Cancer Treat Rep 8: 197207, 1981.Google Scholar
  35. [35]
    Hirsh JD, Conlon PF: Implementing guidelines for managing extravasation of antineoplastics. Am J Hosp Pharm 40: 1516–1519, 1983.PubMedGoogle Scholar
  36. [36]
    David Y, Patish H, Yaffe B, et al: Extravasation injuries. J Orthop Surg Tech 7: 75–86, 1992.Google Scholar
  37. [37]
    Rozencweig M, Kenis Y, Atassi G, et al: DNA-adriamycin complex: preliminary results in animals and men. Cancer Chemother Rep 6: 131–136, 1975.Google Scholar
  38. [38]
    Wilson DW, Grier D, Reimer R, et al: Structure-activity relationship of daunorubicin and its peptide derivatives. J Med Chem 19: 381–384, 1976.PubMedCrossRefGoogle Scholar
  39. [39]
    Haskell CM, Canellos GP, Leventhal BG, et al: L-asparaginase: therapeutic and toxic effects in patients with neoplastic disease. N Engl J Med 281: 1028–1034, 1969.PubMedCrossRefGoogle Scholar
  40. [40]
    Weiss RB, Bruno S: Hypersensitivity reactions to cancer chemotherapeutic agents. Ann Int Med 94: 66–72, 1981.PubMedCrossRefGoogle Scholar
  41. [41]
    Cornwell GG, Pajak TF, McIntyre OR: Hypersensitivity reactions to i.v. melphalan during treatment of multiple myeloma: cancer and leukemia group B experience. Cancer Treat Rep 63: 399–403, 1979.PubMedGoogle Scholar
  42. [42]
    Grem JL, King SA, Costanza ME, et al: Hypersensitivity reactions to trimetrexate. Invest New Drugs 8: 211–214, 1990.PubMedGoogle Scholar
  43. [43]
    Vogelzang NJ: “Adriamycin flare”: a skin reaction resembling extravasation. Cancer Treat Rep 63: 2067–2069, 1979.Google Scholar
  44. [44]
    Chait LA, Dinner MI: Ulceration caused by cytotoxic drugs. S Afr Med J 49: 1935–1936, 1975.PubMedGoogle Scholar
  45. [45]
    Dragon LH, Braine HG: Necrosis of the hand after daunorubicin infusion distal to an arteriovenous fistula. Ann Intern Med 91: 58–59, 1979.PubMedCrossRefGoogle Scholar
  46. [46]
    Tully JL, Friedland GH, Baldini LM, et al: Complications of intravenous therapy with steel needles and teflon® catheters. Am J Med 70: 702–706, 1981.PubMedCrossRefGoogle Scholar
  47. [47]
    Hankin FM, Louis DS: Extravasation of chemotherapeutic agents. Am Fam Physician 31: 147–150, 1985.PubMedGoogle Scholar
  48. [48]
    Levey RH, Sallen S, Weinstein H, et al: Surgical techniques for vascular access for chemotherapy in infants and children. J Pediatr Surg 13: 724729, 1978.Google Scholar
  49. [49]
    Meranze SG, Burke DR, Feurer ID, et al: Spontaneous retraction of indwelling catheters: previously unreported complications. J Parenter Enteral Nutr 12: 310–312, 1988.CrossRefGoogle Scholar
  50. [50]
    Lokich JJ, Moore C: Drug extravasation in cancer chemotherapy. Ann Int Med 104: 124, 1986.PubMedGoogle Scholar
  51. [51]
    Dorr RT, Jones SE: Inapparent infiltrations associated with vindesine administration. Med Pediatr Oncol 6: 285–288, 1979.PubMedCrossRefGoogle Scholar
  52. [52]
    Hessen JA: Protocol for treatment of vesicant antineoplastic extravasation. Hosp Pharm 24: 705–709, 1989.Google Scholar
  53. [53]
    Dorr RT: Antidotes to vesicant chemotherapy extravasations. Blood Rev 4: 41–60, 1990.PubMedCrossRefGoogle Scholar
  54. [54]
    Harwood KV, Aisner J: Treatment of chemotherapy extravasation: current status. Cancer Treat Rep 68: 939–945, 1984.PubMedGoogle Scholar
  55. [55]
    Scuderi N, Onesti MG: Antitumor agents: extravasation, management, and surgical treatment. Ann Plast Surg 32: 39–44, 1999.CrossRefGoogle Scholar
  56. [56]
    Krämer I: Zytostatika-Paravasate-Set. Krankenhauspharmazie 13: 154160, 1992.Google Scholar
  57. [57]
    Bertelli G, Gozza A, Forno GB, et al: Topical dimethylsulfoxide for the prevention of soft tissue injury after extravasation of vesicant cytotoxic drugs: a prospective clinical study. J Clin Oncol 13: 2851–2855, 1995.PubMedGoogle Scholar
  58. [58]
    Owen 0E, Dellatorre DL, van Scott EJ, et al: Accidental intramuscular injection of mechlorethamine. Cancer 45: 2225–2226, 1980.PubMedCrossRefGoogle Scholar
  59. [59]
    Petro JA, Graham WP, Miller SH, et al: Experimental and clinical studies of ulcers induced with adriamycin. Surg Forum 30: 535–537, 1979.PubMedGoogle Scholar
  60. [60]
    Hajarizadeh H, Lebredo L, Barrie R, et al: Protective effect of doxorubicin in vitamin C or dimethylsulfoxide against skin ulceration in the pig. Ann Surg Oncol 1: 411–414, 1994.PubMedCrossRefGoogle Scholar
  61. [61]
    Schwartsmann G, Sander EB, Vinholes J, et al: N-acetylcysteine protects skin lesion induced by local extravasation of doxorubicin in a rat model. Am J Pediatr Hematol Oncol 14: 280–281, 1992.PubMedCrossRefGoogle Scholar
  62. [62]
    Nobbs P, Barr RD: Soft-tissue injury caused by antineoplastic drugs is inhibited by topical dimethyl sulphoxide and alpha tocopherol. Br J Cancer 48: 873–876, 1983.PubMedCrossRefGoogle Scholar
  63. [63]
    Ludwig CU, Stoll HR, Obrist R, et al: Prevention of cytotoxic drug induced skin ulcers with dimethyl sulfoxide (DMSO) and a-tocopherole. Eur J Cancer Clin Oncol 23: 327–329, 1987.PubMedCrossRefGoogle Scholar
  64. [64]
    Averbuch SD, Gaudiano G, Koch TH, et al: Doxorubicin-induced skin necrosis in the swine model: protection with a novel radical dimer. J Clin Oncol 4: 88–94, 1986.PubMedGoogle Scholar
  65. [65]
    Comas D, Mateu J: Treatment of extravasation of both doxorubicin and vincristine administration in a y-site infusion. Ann Pharmacother 30: 244–246, 1996.PubMedGoogle Scholar
  66. [66]
    Kolarié K, Zupanc D, Stahl KW, et al: Verhinderung von Extravasatnekrosen als Komplikation nach intravenöser Zytostatikatherapie. Onkologie 11: 238–240, 1988.CrossRefGoogle Scholar
  67. [67]
    Abbes M, Picard JL, Bourgeon Y, et al: A propos de quarante et une complication locales de chimiothérapie. Ann Chir Plast Esthét 31: 149156, 1986.Google Scholar
  68. [68]
    Tsavaris NB, Karagiaouris P, Tzannou I, et al: Conservative approach to the treatment of chemotherapy-induced extravasation. J Dermatol Surg On-col 16: 519–522, 1990.Google Scholar
  69. [69]
    Kraft A, Weinig S, Edinger M, et al: Anthrazyklin-Extravasate. Der Onkologe 6: 674–686, 2000.CrossRefGoogle Scholar
  70. [70]
    Lane P, Vichi P, Bain DL, et al: Temperature dependence studies of adriamycin uptake and cytotoxicity. Cancer Res 47: 4038–4042, 1987.PubMedGoogle Scholar
  71. [71]
    Dorr RT, Alberts DS, Stone A: Cold protection and heat enhancement of doxorubicin skin toxicity in the mouse. Cancer Treat Rep 69: 431–437, 1985.PubMedGoogle Scholar
  72. [72]
    Herman TS: Temperature dependence of adriamycin, cis-diamminedichloroplatinum, bleomycin, and 1,3-bis(2-chloroethyl)-1-nitrosourea cytotoxicity in vitro. Cancer Res 43: 517–520, 1983.PubMedGoogle Scholar
  73. [73]
    Harwood KV, Gonin R: Short term vs. long term local cooling after doxorubicin (DOX) extravasation: an eastern cooperative oncology group (ECOG) study. Proc ASCO 13: 447, 1994.Google Scholar
  74. [74]
    Harwood KV: Treatment of anthracycline extravasation-recommendations for practice. J Clin Oncol 5: 1705, 1987.PubMedGoogle Scholar
  75. [75]
    Dorr RT, Alberts DS: Vinca alkaloid skin toxicity: antidote and drug disposition studies in the mouse. J Natl Cancer Inst 74: 113–120, 1985.PubMedGoogle Scholar
  76. [76]
    Schneider G: Paravasate von Zytostatika. Diagnostik and Therapie. Aina S. Schneider Verlag, 6th edition: 1–17, 1999.Google Scholar
  77. [77]
    Goodman M, Stewart I, Lydon J, et al: Use caution when managing paclitaxel and taxotere infiltrations. Oncol Nurs Forum 2: 541–542, 1996.Google Scholar
  78. [78]
    David NA: The pharmacology of dimethylsulfoxide 6544. Ann Rev Pharmacol 12: 353–374, 1972.PubMedCrossRefGoogle Scholar
  79. [79]
    Kligman AM: Topical pharmacology and toxicology of dimethyl sulfoxide — part I. JAMA 193: 796–804, 1965.PubMedCrossRefGoogle Scholar
  80. [80]
    Görög P, Kovacs IB: Effect of dimethylsulfoxide (DMSO) on various experimental cutaneous reactions. Pharmacology 2: 313–319, 1969.PubMedCrossRefGoogle Scholar
  81. [81]
    Desai MH, Teres D: Prevention of doxorubicin-induced skin ulcers in the rat and pig with dimethyl sulfoxide (DMSO). Cancer Treat Rep 66: 1371 1374, 1982.Google Scholar
  82. [82]
    Massart C, Le Tellier C, Gibassier J, et al: Modulation by dimethyl sulphoxide of the toxicity induced by cis-diamminedichloroplatinum in cultured thyrocytes. Toxicol in vitro 7: 87–94, 1993.PubMedCrossRefGoogle Scholar
  83. [83]
    Jones MM, Basinger MA, Field L, et al: Coadministration of dimethyl sulfoxide reduces cisplatin nephrotoxicity. Anticancer Res 11: 1939–1942, 1991.PubMedGoogle Scholar
  84. [84]
    Olver IN, Aisner J, Hament A, et al: A prospective study of topical dimethyl sulfoxide for treating anthracycline extravasation. J Clin Oncol 6: 1732 1735, 1988.Google Scholar
  85. [85]
    Bertelli G, Dini D, Forno GB, et al: Hyaluronidase as an antidote to extravasation of vinca alkaloids: clinical results. J Cancer Res Clin Oncol 120: 505–506, 1994.PubMedCrossRefGoogle Scholar
  86. [86]
    Cohen MH: Amelioration of adriamycin skin necrosis: an experimental study. Cancer Treat Rep 63: 1003–1004, 1979.PubMedGoogle Scholar
  87. [87]
    Laurie SW, Wilson KL, Kernahan DA, et al: Intravenous extravasation injuries: the effectiveness of hyaluronidase in their treatment. Ann Plast Surg 13: 191–194, 1984.PubMedCrossRefGoogle Scholar
  88. [88]
    Disa JJ, Chang RR, Mucci SJ, et al: Prevention of adriamycin-induced full-thickness skin loss using hyaluronidase infiltration. Plast Reconstr Surg 101: 370–374, 1998.PubMedCrossRefGoogle Scholar
  89. [89]
    Stanley A: Managing complications of chemotherapy. In: Allwood M, Stanley A, Wright P (eds) The Cytotoxics Handbook. Radcliffe Medical Press, 3rd edition: 105–124, 1997.Google Scholar
  90. [90]
    Schwartzman J, Henderson AT, King WE: Hyaluronidase in fluid administration. J Pediatr 33: 267–273, 1948.PubMedCrossRefGoogle Scholar
  91. [91]
    Bartkowski-Dodds L, Daniels JR: Use of sodium bicarbonate as a means of ameliorating doxorubicin-induced dermal necrosis in rats. Cancer Che-mother Pharmacol 4: 179–181, 1980.Google Scholar
  92. [92]
    Barr RD, Sertic J: Soft-tissue necrosis induced by extravasated cancer chemotherapeutic agents: a study of active intervention. Br J Cancer 44: 267–269, 1981.PubMedCrossRefGoogle Scholar
  93. [93]
    Laskar PA, Ayres JW: Degradation of carmustine in aqueous media. J Pharm Sci 66: 1073–1076, 1977.PubMedCrossRefGoogle Scholar
  94. [94]
    Colvin M, Hartner J, Summerfield M: Stability of carmustine in the presence of sodium bicarbonate. Am J Hosp Pharm 37: 677–678, 1980.PubMedGoogle Scholar
  95. [95]
    Schneider SM, Distelhorst CW: Chemotherapy-induced emergencies. Semin Oncol 16: 572–578, 1989.PubMedGoogle Scholar
  96. [96]
    Jackson IT, Robinson DW: Severe tissue damage following accidental subcutaneous infusion of bicarbonate solution. Scot Med J 21: 200–201, 1976.PubMedGoogle Scholar
  97. [97]
    Gaze NR: Tissue necrosis caused by commonly used intravenous infusions. Lancet 2: 417–419, 1978.PubMedCrossRefGoogle Scholar
  98. [98]
    Kappel B, Hindenburg AA, Taub RN: Treatment of anthracycline extravasation — a warning against the use of sodium bicarbonate. J Clin Oncol 5: 825–826, 1987.PubMedGoogle Scholar
  99. [99]
    Groos E, Walker L, Masters JR: Intravesical chemotherapy: studies on the relationship between pH and cytotoxicity. Cancer 58: 1199–1203, 1986.PubMedCrossRefGoogle Scholar
  100. [100]
    Tsavaris NB, Komitsopoulou P, Karagiaouris P, et al: Prevention of tissue necrosis due to accidental extravasation of cytostatic drugs by a conservative approach. Cancer Chemother Pharmacol 30: 330–333, 1992.PubMedCrossRefGoogle Scholar
  101. [101]
    Howell SB, Taetle R: Effect of sodium thiosulfate on cis-dichloroammineplatinum (II) toxicity and antitumor activity in L1210 leukemia. Cancer Treat Rep 64: 611–616, 1980.PubMedGoogle Scholar
  102. [102]
    Buchanan GR, Buchsbaum HJ, O’Banion K, et al: Extravasation of dactinomycin, vincristine, and cisplatin: studies in an animal model. Med Pediatr Oncol 13: 375–380, 1985.PubMedCrossRefGoogle Scholar
  103. [103]
    Dorr RT, Soble M, Alberts DS: Efficacy of sodium thiosulfate as a local antidote to mechlorethamine skin toxicity in the mouse. Cancer Chemother Pharmacol 22: 299–302, 1988.PubMedCrossRefGoogle Scholar
  104. [104]
    Baskin SI, Horowitz AM, Nealley EW: The antidotal action of sodium nitrite and sodium thiosulfate against cyanide poisoning. J Clin Pharmacol 32: 368–375, 1992.PubMedCrossRefGoogle Scholar
  105. [105]
    Dorr RT, Alberts DS, Chen HS: The limited role of corticosteroids in ameliorating experimental doxorubicin skin toxicity in the mouse. Cancer Chemother Pharmacol 5: 17–20, 1980.PubMedCrossRefGoogle Scholar
  106. [106]
    Coleman JJ, Walker AP, Didolkar MS: Treatment of adriamycin-induced skin ulcers: a prospective controlled study. J Surg Oncol 22: 129–135, 1983.PubMedCrossRefGoogle Scholar
  107. [107]
    Rudolph R: Ulcers of the hand and wrist caused by doxorubicin hydrochloride. Orthop Rev 7: 93–95, 1978.Google Scholar
  108. [108]
    Luedke DW, Kennedy PS, Rietschel RL: Histopathogenesis of skin and subcutaneous injury induced by adriamycin. Plast Reconstr Surg 63: 463465, 1979.Google Scholar
  109. [109]
    Rudolph R, Larson DL: Etiology and treatment of chemotherapeutic agent extravasation injuries: a review. J Clin Oncol 5: 1116–1126, 1987.PubMedGoogle Scholar
  110. [110]
    Larson DL: What is the appropriate management of tissue extravasation by antitumor agents? Plast Reconstr Surg 75: 397–402, 1985.PubMedCrossRefGoogle Scholar
  111. [111]
    Pitkänen J, Asko-Seljavaara S, Gröhn P, et al: Adriamycin extravasation: surgical treatment and possible prevention of skin and soft-tissue injuries. J Surg Oncol 23: 259–262, 1983.PubMedCrossRefGoogle Scholar
  112. [112]
    Shenaq SM, Abbase EH, Friedman JD: Soft-tissue reconstruction following extravasation of chemotherapeutic agents. Surg Oncol Clin N Am 5: 825–845, 1996.PubMedGoogle Scholar
  113. [113]
    Seyfer AE, Solimando DA: Toxic lesions of the hand associated with chemotherapy. J Hand Surg 8: 39–42, 1983.Google Scholar
  114. [114]
    Devereux DF, Thibault LE, Boretos J, et al: Th`e quantitative and qualitative impairment of wound healing by adriamycin. Cancer 43: 932–938, 1979.PubMedCrossRefGoogle Scholar
  115. [115]
    Devereux DF, Kent H, Brennan MF: Time dependent effects of adriamycin and x-ray therapy on wound healing in the rat. Cancer 45: 2805–2810, 1980.PubMedCrossRefGoogle Scholar
  116. [116]
    Devereux DF, Triche TJ, Webber BL, et al: A study of adriamycin-reduced wound breaking strength in rats. Cancer 45: 2811–2815, 1980.PubMedCrossRefGoogle Scholar
  117. [117]
    Cohen FJ, Manganaro J, Bezozo RC: Identification of involved tissue during surgical treatment of doxorubicin-induced extravasation necrosis. J Hand Surg 8: 43–45, 1983.Google Scholar

Copyright information

© Springer-Verlag Wien 2003

Authors and Affiliations

  • Ines Mader
    • 1
  • Patrizia E. Fürst-Weger
    • 2
  • Robert M. Mader
    • 3
  • Elisabeth I. Semenitz
    • 4
  • Robert Terkola
    • 5
  • Sabine M. Wassertheurer
    • 6
  1. 1.Austrian Breast and Colorectal Cancer Study GroupViennaAustria
  2. 2.SMZ FloridsdorfKrankenhaus und GeriatriezentrumViennaAustria
  3. 3.Clinical Division of Oncology, Department of Medicine IUniversity HospitalViennaAustria
  4. 4.AnstaltsapothekeLandeskrankenhaus — Universitätskliniken InnsbruckAustria
  5. 5.Kaiser-Franz-Josef HospitalViennaAustria
  6. 6.Apotheke LKH-Univ.-Klinikum GrazAustria

Personalised recommendations